Cost Comparison of Efanesoctocog Alfa vs Conventional Factor VIII Therapies for Major Surgeries in Severe Hemophilia A

Janice M. Staber; Alix Arnaud; Ion Agirrezabal; Duygu Bozkaya; Lane Anson; Andrew Wilson; Nana Kragh; Doris Quon; Allison P. Wheeler

doi:10.1016/j.bvth.2026.100166

Back

Cost Comparison of Efanesoctocog Alfa vs Conventional Factor VIII Therapies for Major Surgeries in Severe Hemophilia A

Journal article

Open access

Peer reviewed

Cost Comparison of Efanesoctocog Alfa vs Conventional Factor VIII Therapies for Major Surgeries in Severe Hemophilia A

Janice M. Staber, Alix Arnaud, Ion Agirrezabal, Duygu Bozkaya, Lane Anson, Andrew Wilson, Nana Kragh, Doris Quon and Allison P. Wheeler

Blood Vessels, Thrombosis & Hemostasis, 100166

03/2026

DOI: 10.1016/j.bvth.2026.100166

Files and links (1)

url

https://doi.org/10.1016/j.bvth.2026.100166View

Published (Version of record) Open Access

Abstract

We estimated total costs for perioperative hemostatic management with standard half-life (SHL), extended half-life (EHL) and high-sustained (efanesoctocog alfa) factor VIII (FVIII) products in people with severe hemophilia A. The data on dose, total factor consumption and target FVIII activity for major surgeries were collected from United States (US) prescribing information and phase 3 clinical trials. The differences in the total factor consumption and total costs between therapies were compared. The median total factor consumption per major surgery involving octocog alfa (SHL), rurioctocog alfa pegol (EHL), efmoroctocog alfa (EHL) and efanesoctocog alfa was 910, 629, 493 and 163 IU/Kg, respectively. The total factor costs were $162,308, $147,104, $120,233 and $81,286, respectively. Efanesoctocog alfa resulted in $81,022 to $38,947 savings versus SHL/EHL therapies per surgery. The perioperative management with efanesoctocog alfa was estimated to be markedly more economical than that with SHL and EHL therapies due to its high-sustained factor activity.

Details

Title: Subtitle: Cost Comparison of Efanesoctocog Alfa vs Conventional Factor VIII Therapies for Major Surgeries in Severe Hemophilia A
Creators: Janice M. Staber - University of Iowa Stead Family Children’s Hospital
Alix Arnaud - Sanofi (United States)
Ion Agirrezabal - Sanofi (Spain)
Duygu Bozkaya - Sanofi (United States)
Lane Anson - Sanofi (United States)
Andrew Wilson
Nana Kragh - Swedish Orphan Biovitrum (Sweden)
Doris Quon - National Hemophilia Foundation
Allison P. Wheeler - University of Washington Medical Center
Resource Type: Journal article
Publication Details: Blood Vessels, Thrombosis & Hemostasis, 100166
DOI: 10.1016/j.bvth.2026.100166
ISSN: 2950-3272
eISSN: 2950-3272
Language: English
Electronic publication date: 03/2026
Academic Unit: Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Hematology/Oncology
Record Identifier: 9985149708902771

Metrics

1 Record Views